Predicting responders to therapies for multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Predicting responders to therapies for multiple sclerosis.

Predicting responders to therapies for multiple sclerosis.

http://www.wikidata.org/entity/Q37606292

about

Clinical correlates of grey matter pathology in multiple sclerosis Personalized medicine in multiple sclerosis: hope or reality?Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration.Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme.Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).Transient oscillatory dynamics of interferon beta signaling in macrophages Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey.Utility of the rio score and modified rio score in korean patients with multiple sclerosis.A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Determinants of interferon β efficacy in patients with multiple sclerosis.Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis.Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.The emerging agenda of stratified medicine in neurology.Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice.The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis.The role of glatiramer acetate in the early treatment of multiple sclerosis Defining and scoring response to IFN-β in multiple sclerosis.MS lesions are better detected with 3D T1 gradient-echo than with 2D T1 spin-echo gadolinium-enhanced imaging at 3T.Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis.Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

P2860

Q26999302-BF17A04C-BBC8-45AC-8855-F2468B031A2E Q27025933-0858D879-85E6-4707-A963-5842877CB1AF Q28080043-52B5AA9F-D160-403E-A657-E695C1EB9B02 Q28261215-533EF54A-C76A-4CC5-BCF3-DB5840F1FE09 Q34303664-4B0EBC70-8166-46C8-A831-B461CE136F73 Q34557520-030FAE82-AD9C-4C25-9787-86C80948DECB Q34566243-E221244F-E326-4CF3-BC61-46A16C2F969C Q34803273-CA3246F5-DEE9-415E-915F-2C3A28FA3220 Q34812643-528ECAB5-8040-4C08-AEBE-328A43DA1AF7 Q35078327-6E046AE3-37F8-499F-9560-A4F10116975E Q35148010-D2AE8B4E-ED61-4F8A-9528-ADFA23EBE3BD Q35280670-88318ADA-8D2E-4785-AF1C-472BA60B1A6A Q35641688-1B27C5E9-A0C0-44E2-8662-A2F4B2C64CDA Q36075481-B0AAB4A4-6EDD-40EA-BAF6-7E7A364BD5C9 Q36352813-9EB12F51-DD3C-4E8D-9424-E171D737B110 Q37848651-C1FFF841-A557-4138-AD41-1F7ADF02E9AE Q37859376-027784D1-804C-4F5C-B3A1-008C280EADBE Q37995056-FED36930-16CD-4FC4-8870-F893FA7D702D Q38121632-4726B59A-4991-492E-9276-932432D603A6 Q38163046-5A3DA320-0176-4406-AE7B-AFB5FB195094 Q38169977-99037B32-2F2D-4993-B003-66BBDC4253B7 Q38202636-F4BED901-C71B-4652-B71B-7E946FC83116 Q38374486-5438C9E6-3F0B-47D3-81F0-9CB8DC9D1F5D Q38375605-9267BE6D-3A22-4423-A5E6-FB5C3751F97A Q38587671-DFD61E97-9F0B-4487-80EB-2F8309575A97 Q38910574-DB2A00AD-828D-4320-B76E-360404CB6FE0 Q41026569-48B288A1-F554-40A6-8DCB-C49F1EE41BB1 Q41840532-9DFED139-67AD-4733-8028-71F2A322D4F2 Q46023940-F32574D8-EAAB-4F51-B5F9-1171F24037FA Q46107796-3B22A0FE-217E-400E-9D14-6C970BF8B57C Q51154524-841F8FC9-8411-416F-9BC0-DA3816DD5465 Q51381933-9FA485DD-4C5A-4181-8202-A99B99C5C94C Q52897470-A91D7219-94EC-4179-B492-1D40A22E0CB6 Q53080613-79772653-93FC-42DC-8531-954B91F50F20 Q53841734-BFBB9023-40C8-47C3-BF61-28D88B79E95E Q55379969-0FC0AB89-D19D-4664-AAEC-B6CCB5C7DEA5 Q55559824-0D53923C-E9D5-4E65-9938-C21984756339 Q57601819-C67E3243-0C56-4CDD-89A6-C73FEA6D1073 Q57601861-B91DAD49-F253-48DB-8209-30EC830515B9

P2860

Predicting responders to therapies for multiple sclerosis.

http://www.wikidata.org/entity/Q37606292

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Predicting responders to therapies for multiple sclerosis.

@en

Predicting responders to therapies for multiple sclerosis.

@nl

type

label

Predicting responders to therapies for multiple sclerosis.

@en

Predicting responders to therapies for multiple sclerosis.

@nl

prefLabel

Predicting responders to therapies for multiple sclerosis.

@en

Predicting responders to therapies for multiple sclerosis.

@nl

P1433

Q37606292-204E811F-F154-406D-9A86-8E1B51230D97

P1476

Q37606292-C349D40F-B4F4-46DD-8089-1CF413E8A732

P2093

Q37606292-42609F46-9E39-4DF3-9196-692E8E3F3D00

Q37606292-4F72EAFE-DDFB-445D-804E-0B9DFD7B397A

Q37606292-E47186C9-B859-43D7-83A7-A4FD702EE690

P2860

Q37606292-11B4FDDF-47CB-4741-A678-FBAFDD6E7B47

Q37606292-50B94C03-C5EC-4AB5-8877-C45BFA3CD3BC

Q37606292-6542E7D5-4ABE-4F8E-80EE-ED7B1767D64E

Q37606292-BBE05234-9E00-442B-82AE-050F36984153

Q37606292-D330A7EA-3F06-43D1-BDA6-05B6AE986FA6

Q37606292-D63ABE21-A01A-4920-97B9-792739654029

Q37606292-E6E1CFDF-62D4-4D21-8370-2BA837E75D56

P2888

Q37606292-4B181244-5687-43C7-AC1A-647CD42EBF73

P304

Q37606292-D091D39F-7649-4F88-BD03-73E4A449F9CE

P31

Q37606292-F90D8267-F582-4AF8-B766-26B5CAF9A4C6

P356

Q37606292-FD79F282-2616-4F9E-AA31-57C7C29ED308

P407

Q37606292-16C70EB3-DC41-4A21-A326-64774AA3CF0A

P433

Q37606292-0424521A-B740-426B-9972-4991D7FAFD3E

P478

Q37606292-3D76EAEF-8AD5-48B3-9869-B5F6CB7E8AC4

P577

Q37606292-BCC9B1B8-102C-4A86-8669-5F0ACD389D3E

P6179

Q37606292-4CEEF334-7C97-46DE-9D6C-BC4AAD466F34

P698

Q37606292-AD42E05D-A0BD-4A32-9F48-A53B48D68ED7

P921

Q37606292-C8B9272E-10D8-4D2A-BBF7-5DBD6EF8D98F

P356

NRNEUROL.2009.139

P1433

Nature Reviews Neurology

P1476

Predicting responders to therapies for multiple sclerosis.

@en

P2093

Jordi Río

http://www.w3.org/2001/XMLSchema#string

Manuel Comabella

http://www.w3.org/2001/XMLSchema#string

Xavier Montalban

http://www.w3.org/2001/XMLSchema#string

P2860

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Clinical characteristics of responders to interferon therapy for relapsing MS.

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

P2888

nrneurol.2009.139

P304

553-560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEUROL.2009.139

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002089713

http://www.w3.org/2001/XMLSchema#string

P698

19794514

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis